Which feature best distinguishes statins from fibrates in their mechanism of action and lipid-lowering efficacy?

## Mechanism and Efficacy Comparison ### Statins **Key Point:** Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, leading to upregulation of LDL receptors and potent LDL-C reduction (30–50%). - Primary effect: **LDL-C reduction** (most potent class) - Secondary effect: modest triglyceride reduction (~10–20%) - Modest HDL-C increase (~5–10%) ### Fibrates **Key Point:** Fibrates activate peroxisome proliferator-activated receptor-alpha (PPAR-α), which upregulates lipoprotein lipase and apoA-I synthesis. - Primary effect: **Triglyceride reduction** (40–50%, especially in hypertriglyceridemia) - Secondary effect: modest LDL-C reduction (especially in Type III hyperlipoproteinemia) - Modest HDL-C increase (~10–15%) ### Comparative Table | Feature | Statins | Fibrates | | --- | --- | --- | | **Primary target** | LDL-C (↓30–50%) | Triglycerides (↓40–50%) | | **Mechanism** | HMG-CoA reductase inhibition | PPAR-α activation | | **Best for** | High LDL-C, CAD prevention | High TG, low HDL-C | | **HDL-C effect** | Modest ↑5–10% | Modest ↑10–15% | | **Drug interaction risk** | Moderate (CYP3A4) | High (protein binding displacement) | **High-Yield:** The **discriminating feature** is the primary lipid target and the molecular mechanism — statins excel at LDL reduction via cholesterol synthesis blockade; fibrates excel at triglyceride reduction via lipoprotein lipase activation. **Clinical Pearl:** In a patient with elevated LDL-C and normal triglycerides, statin is first-line. In a patient with elevated triglycerides and low HDL-C, fibrate is preferred. Combined therapy (statin + fibrate) is used cautiously due to myopathy risk. [cite:KD Tripathi 8e Ch 32]